June 6, 2010

Prophylactic Eculizumab after Renal Transplantation in Atypical Hemolytic–Uremic Syndrome


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Hemolytic-uremic syndrome (HUS) can be due to one of several mutations in an element of the complement cascade. There is a high incidence of recurrence and graft loss after renal transplantation. In this case report, a child with HUS due to a complement factor H mutation received prophylactic treatment with the complement inhibitor eculizumab following transplantation, preventing recurrent HUS. This patient requires ongoing treatment with eculizumab, which is very expensive.

Renal Transplantation